Benralizumab
Benralizumab is a biological therapy with 61 clinical trials. Currently 11 active trials ongoing. Historical success rate of 80.0%.
Success Metrics
Based on 32 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
13
Mid Stage
39
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
80.0%
32 of 40 finished
20.0%
8 ended early
11
trials recruiting
61
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
Clinical Trials (61)
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
Fasenra: An Asthma Study
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
Effect of Benralizumab in Atopic Dermatitis
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI
Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis
Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging
FAsenra Safety Trial in India
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 61